

**INDIANA HEALTH COVERAGE PROGRAMS (IHCP) PHARMACY BENEFIT
VAGINAL ANTIMICROBIALS PRIOR AUTHORIZATION REQUEST FORM**



OptumRx
P.O. Box 25184
Santa Ana, CA, 92799
Phone: (866) 215-5046 Fax: (866) 940-7328



Today's Date

□□ / □□ / □□□□

Note: This form must be completed by the prescribing provider.

****All sections must be completed or the request will be returned****

Patient's Medicaid #	□□□□□□□□□□	Date of Birth	□□ / □□ / □□□□
Patient's Name	Prescriber's Name		
Prescriber's IN License #	□□□□□□□□	Specialty	
Prescriber's NPI #	□□□□□□□□□□	Prescriber's Signature	
Return Fax #	□□□□ - □□□□ - □□□□	Return Phone #	□□□□ - □□□□ - □□□□
Check box if requesting retro-active PA	<input type="checkbox"/>	Date(s) of service requested for retro-active eligibility (if applicable):	

Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).

Requested Medication	Strength	Dosage Regimen

PA Requirements for BREXAFEMME (ibrexafungerp):

- One of the following diagnoses:
 - Diagnosis of acute vulvovaginal candidiasis
 - Diagnosis of recurrent vulvovaginal candidiasis (must provide documentation of 3 or more episodes of vulvovaginal candidiasis within the past year)
- For members less than 18 years of age: provider attests member is postmenarchal Yes No
 Provider printed name and signature: _____
- Documentation of a negative pregnancy test within the past 30 days attached Yes No
- Member has a trial and failure history of oral fluconazole within the past year Yes No
 If no, provide medical rationale supporting use of Brexafemme (ibrexafungerp) over oral fluconazole

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.

PA Requirements for VIVJOA (oteseconazole):

1. Diagnosis of recurrent vulvovaginal candidiasis Yes No

Note: provide documentation of 3 or more episodes of vulvovaginal candidiasis experienced by member within the past year

2. Member is 18 years of age or older Yes No

3. Provider attests member is not considered to be of reproductive potential Yes No

4. Member has a trial and failure history of oral fluconazole within the past year Yes No

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.